January 21, 2021
Consumer telehealth and wellness brand Hims & Hers wrapped up its merger with special purpose acquisition company (SPAC) Oaktree Acquisition Tuesday, and today began trading on the New York Stock Exchange.
The deal was first announced in October, and was originally expected to close before the end of its Q4 2020. After Tuesday's approval, the deal has provided Hims with $279.5 million, $205...
October 29, 2020
Digital pharmacy Hims & Hers has reported 91% year-over-year growth during the third quarter of this year.
This comes just weeks after the company announced a merger agreement with Oaktree Capital Management-sponsored special purpose acquisition company (SPAC) Oaktree Acquisition. The public can expect the reverse merger to close at the end of the fourth quarter of 2020.
Hims made a name...
October 1, 2020
Consumer-friendly telehealth and mail-order wellness product service Hims is officially entering the public markets. Today it announced a merger agreement with Oaktree Capital Management-sponsored special purpose acquisition company (SPAC) Oaktree Acquisition Corp.
The reverse merger is expected to close in the fourth quarter of 2020, and places the combined entity at a roughly $1.6 billion...
September 11, 2020
About the authors: Andrew Dudum is the CEO and founder of Hims & Hers, a consumer-facing digital health company offering telehealth services.
Joel White is executive director of the Health Innovation Alliance, a coalition of health and technology leaders who support policies that use technology and data to make healthcare work better.
Outside of these positions, Dudum and White report no...
August 3, 2020
Austin, Texas-based virtual and on-demand care provider Remedy announced Dr. Ronald Dixon as its chief medical officer. Dixon, formerly the head of clinical affairs at Onduo and the president and CEO of Onduo Professionals (its provider staffing group), is expected to draw on his experience to help Remedy build out its virtual chronic care treatment services.
“Dr. Dixon’s experience in developing...
July 30, 2020
D2C wellness and telehealth startup Hims & Hers is looking to cut down the time between medication orders and delivery for certain customers.
Thanks to a newly announced partnership, patients receiving virtual primary care services through Hims & Hers may choose to select Alto as their preferred pharmacy for prescription deliveries. They will have their orders fulfilled automatically ...
July 23, 2020
Consumer wellness and telehealth company Hims could be the next to throw its hat into the public markets.
According to a report from Reuters, the startup is weighing a potential sale to an unnamed special purpose acquisition company (SPAC) – a "blank-check company" that uses the proceeds of an IPO to acquire or merge another business.
The deal would value Hims at over $1 billion, Reuters' sources...
May 13, 2020
Less than a week after the first home-collected saliva test for COVID-19 was authorized by the FDA, at least two consumer-facing telehealth brands say they have cut deals to sell these test kits to the public.
The first is consumer telehealth company Hims & Hers, best known for its mail-order wellness and sexual health products for men and women.
While the well-funded startup has...
April 8, 2020
Easy access to (temporarily) free counseling. Consumer telehealth and mail-order prescription services Hims and Hers are dipping into the mental health wellness space. The brands kicked off new anonymized group therapy and guided meditation offerings yesterday, with the therapy sessions led by a licensed mental health practitioner.
The group sessions are currently being offered free of charge in...
November 14, 2019
Hims & Hers, an online mail-order health company that uses remote consultations to prescribe cosmetic and sexual health products, has rolled out a new app for users.
The app will offer almost identical services and links as the original platform, and will give users access to asynchronous healthcare visits and prescription products such as birth control and erectile dysfunction medication...